Stem Cell Manufacturing Market, By Type (Product, Services), By Application (Stem Cell Therapy, Drug Discovery and Development, Stem Cell Banking), By End-User (Pharmaceutical and Biotechnology Companies & CRO, Cell Banks and Tissue Banks, Academic & Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2024

Code : CMI5381

Pages :168

Formats :

Excel and PDF

Industry : Biotechnology

Stem Cell Manufacturing Market Size and Trends

Global Stem Cell Manufacturing market is estimated to be valued at USD 12.8 Bn in 2024 and is expected to reach USD 30.2 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13% from 2024 to 2031.

Stem Cell Manufacturing Market Key Factors

To learn more about this report, request sample copy

The market is driven by factors such as rising prevalence of chronic diseases, growing R&D in drug discovery and regenerative medicine, and increasing investments in stem cell research. The stem cell manufacturing market trend involves adoption of automation and closed system process technologies to develop advanced stem cell therapeutics. As stem cell therapy becomes applicable across various clinical indications, market players are focusing on enhancing stem cell culture, isolation, and cryopreservation techniques. Additionally, the integration of continuous manufacturing with digitization presents lucrative opportunities for stem cell therapy commercialization in the coming years. For instance, In January 2024, according to a study published in the Journal of the American Heart Association found that the global prevalence of heart failure reached 56.19 million cases, highlighting the increasing burden of chronic cardiovascular diseases

Rising prevalence of chronic diseases

The global burden of chronic diseases has been steadily increasing over the past few decades. Chronic diseases such as cancer, cardiac ailments, diabetes, neurological disorders have become major public health challenges across both developed and developing world. The global stem cell manufacturing market is projected to expand due to the increasing prevalence of chronic and neurological disorders. Stem cells offer potential for replacing damaged neurons caused by conditions like spinal cord injuries, Parkinson’s disease, and Alzheimer's disease. Stem cell therapy presents a viable option for treating Parkinson's disease, which has seen a doubling in global prevalence over the past 25 years, with more than 8.5 million individuals affected as of 2020, For Instance according to the World Health Organization (WHO)In February 2020, Rising awareness of the therapeutic potential of stem cells is anticipated to drive market growth. Stem cells are now routinely utilized by doctors in treating cancer and various blood and immune system disorders. WHO reports that cancer remains a leading cause of death worldwide, claiming nearly 10 million lives in 2020, representing nearly one in six deaths. Breast, lung, colon and rectum, and prostate cancers are among the most common types. Consequently, market players are focusing on introducing novel stem cell therapies for cancer treatment.

/p>

Rise in the number of approvals partnerships relating to stem cell therapy

The market is anticipated to experience growth driven by an increase in approvals and partnerships related to stem cell therapy. For instance, in March 2021, Vertex Pharmaceuticals obtained FDA fast-track designation for VX-880, a human stem cell-derived therapy intended for patients with Type 1 diabetes. VX-880 represents a pioneering allogeneic, fully differentiated islet cell therapy aimed at regulating glucose levels by reinstating pancreatic islet cell function, including insulin production.